

What is claimed:

1. A method for treating heart failure after myocardial infarction in a subject, comprising:
 - a) administering an angiotensin II (AT₁) receptor blocker to said subject for a period beginning about the time of myocardial infarction to about ten weeks; and
 - b) administering growth hormone beginning about ten weeks after myocardial infarction.
2. The method of claim 1, wherein angiotensin II (AT₁) receptor blocker administration is discontinued about 10 weeks after myocardial infarction.
3. The method of claim 1, wherein said AT₁ receptor blocker comprises losartan.
4. A method of treating heart failure in a subject following an ischemic event, comprising:
 - a) administering an angiotensin II inhibitor to said subject over a period beginning about the time of said ischemic event, and continuing for a period sufficient to substantially permit favorable left ventricular remodeling; and
 - b) administering a growth hormone to said subject at a time approximately after said ventricular remodeling period.
5. The method of claim 4, wherein administration of said angiotensin II inhibitor is discontinued at about the time growth hormone administration begins.
6. The method of claim 4, wherein said angiotensin II inhibitor comprises an AT₁ receptor inhibitor.
7. The method of claim 6, wherein said AT₁ receptor inhibitor comprises losartan.
8. The method of claim 4, wherein said growth hormone is human growth hormone.
9. The method of claim 4, wherein said angiotensin II inhibitor is administered beginning within seven days of said ischemic event.
10. The method of claim 9, wherein said angiotensin II inhibitor is administered for about 8 to about 12 weeks.
11. The method of claim 10, wherein said angiotensin II inhibitor is administered for about 10 weeks.
12. The method of claim 9, wherein said growth hormone is administered for about one to about three weeks.
13. The method of claim 4, wherein said growth hormone is administered for about two weeks.

14. The method of claim 4, wherein said angiotensin II inhibitor is administered at a reduced dosage after said ventricular remodeling period.

15. The method of claim 14, wherein said reduced dosage is less than about one half the dosage prior to the end of said ventricular remodeling period.

16. The method of claim 4, wherein steps a) and b) are repeated.